Table 3.
A table to show the previous studies performed evaluating the clinical outcomes of DMEK after glaucoma surgery.
| Paper | Number of patients | Previous glaucoma surgery | Length of follow-up | VA improvement | Rate of ECD loss postop | Primary graft failure | Rebubbling rates | Secondary graft failure | Postoperative IOP |
|---|---|---|---|---|---|---|---|---|---|
| Alshaker et al., 2021 [160] |
N = 48 DMEK, N = 41 DSAEK |
62.5% tube, 37.5% trab only, 61.0% tube, 39.0% trab only |
30.0 ± 15.5 months, 33.9 ± 22.5 months |
Postoperative BCVA was significantly better in DMEK group at 24 months (p = 0.047) | 57%, 50% (p = 0.886) at 36 months |
14.6%, 14.6% (p = 1.0) |
25.0%, 19.5% (P = 0.615 |
20.8%, 19.5% (p = 1.0) |
14.6%, 17.1% (IOP: 25–45 mmHg) (P = 0.768) |
| Fili et al., 2021 [161] |
N = 16 DMEK, N = 9 DSAEK, N = 15 PK |
68.8% trab, 43.8% tube, 100.0% trab, 22.2% tube, 80.0% trab, 40% tube, |
24 months | Final BCVA at 24 months 0.34 ± 0.29 0.17 ± 0.18 0.06 ± 0.07 |
50.7%, 48.9%, 42.7% at 12 months (P < 0.45) |
6.25%, 11.11%, 0 |
N/A | 12.5%, 33.33%, 13.33% |
6.25%, 11.11%, 0 |
| Bonnet et al., 2020 [158] |
N = 11 medically treated GL, N = 38 surgically treated Gl, N = 41 no GL |
55.3% previous trab, 68.4% previous tube | 38.4 ± 11.2 months | Achieved BCVA of ≥20/20, 46%, 8%, 49% (p < 0.01) |
47.6%, 63.8%, 44.0% (p < 0.05) |
0%, 0%, 0% |
18.2%, 15.8%, 19.5% (p = 0.93) |
0%, 41.6%, 2.4% (p < 0.05) |
54.5%, 26.3%, 34.1% (IOP >24 mm Hg or >8 increase) (p = 0.21) |
| Sorkin et al., 2020 [162] |
N = 51 surgically treated Gl, N = 43 controls |
49.0% previous tube, 13.7% trab and tube, 37.3% previous trab |
37.9 ± 15.2 months, 33.8 ± 13.5 months |
Mean BCVA improved from 1.82 ± 0.88 logMAR preop to 1.06 ± 0.87 at 6 months (no comparison to controls) | 74%, 52% at 48 months (P = 0.004) |
15.7%, 11.6% P = 0.766 |
23.5%, 30.2% P = 0.491 |
47.1%, 0% P < 0.001 |
7.8% (control group not reported) |
| Boutin et al., 2020 [163] | N = 27 | 44.4% prior tube, 33.3% prior trab, 14.8% trab and tube, 3.7% trab and gold Microshunt, 3.7% prior tube and hydrus |
14.6 ± 6.1 months | Mean BCVA improved from 1.34 ± 0.65 logMAR preop to 0.50 ± 0.33 at 1 year | 50.4% at one year (P = 0.001) |
3.7% | 18.5% | 10.3% | 3.7% |
| Lin et al., 2019 [164] |
N = 46 DMEK N = 46 DSEK |
48% prior trab, 78% prior tube, 50% prior trab, 74% prior tube |
12 months | Improved by -0.89 logMAR, -0.62 logMAR (p = 0.005) |
N/A N/A |
2% 2% (p = 0.65) |
22% 9% (p = 0.14) |
0% 17% (p = 0.006) |
30% IOP elevation, 36% IOP elevation (increase >8 mmHg) (p = 0.66) |
| Birbal et al., 2018 [153] | N = 23 | 65% trabeculectomy, 100% tubes (85% 1 tube, 15% 2 tubes) |
19 ± 17 months | BCVA improved by ≥ 2 Snellen lines in 73% | 71% | 8.7% | 21.7% | 8.7% | 9% (IOP >24 mmHg or >10 mmHg increase) |
| Aravena et al., 2017 [165] |
N = 14 medically treated GL, N = 34 surgically treated Gl, N = 60 no GL |
52.9% tube only, 14.7% trab and tube, 32.3% trab only |
9.7 ± 7.3 months | Achieved BCVA of ≥20/25, 71.4%, 32.4%, 62.6% P < 0.0001 |
29.9 ± 12.0%, 44.6 ± 17.8%, 32.7 ± 11.3%, P = 0.001 |
0, 0, 1.7% P = 1.0 |
21.4%, 23.5%, 23.3% |
0, 0, 0 |
50.0%, 14.7%, 23.3% (p = 0.001) |
N: number; DMEK: Descemet membrane endothelial keratoplasty; DSAEK: Descemet striping automated endothelial keratoplasty; BCVA: best corrected visual acuity; ECD: endothelial cell density; IOP: intraocular pressure; GL: glaucoma.